The Claim
Testosterone-replacement therapy has no statistically significant effect on cardiovascular mortality in middle-aged and older men with low testosterone after at least 12 months of treatment, with a relative risk of 0.85 (95% CI 0.65–1.12).
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In middle-aged and older men with low testosterone, testosterone-replacement therapy does not change the risk of dying from cardiovascular disease compared to no treatment, based on a 12-month or longer observation period.
See the scientific wording
Testosterone-replacement therapy does not significantly affect the risk of cardiovascular mortality in middle-aged and older men with low testosterone, with a relative risk of 0.85 (95% CI 0.65–1.12), indicating no statistically significant benefit or harm compared to placebo after at least 12 months of treatment.
Adding testosterone back into men with low levels does not change how the heart and blood vessels handle stress, so the chance of dying from heart problems stays the same as if nothing was added.
What the research says
1 studyIn older men with low testosterone, taking testosterone therapy didn’t make them more or less likely to die from heart problems compared to those who didn’t take it, based on a big study of thousands of men.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.